ArticleProtein science : a publication of the Protein Society2025
Investigating the unbinding mechanisms and kinetics of MmpL3 inhibitors: A computational study.
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating computational and biological approaches for the discovery of putative MmpL3 inhibitors against Mycobacterium tuberculosis.Molecular diversity · 2026Article
- Investigating the unbinding mechanisms and kinetics of MmpL3 inhibitors: A computational study.Protein science : a publication of the Protein Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mycobacterial membrane protein Large 3 (MmpL3) is responsible for transporting trehalose monomycolates across the inner membrane for cell wall biosynthesis, a process driven by the proton motive force and essential for the survival of Mycobacterium tuberculosis. As a result, MmpL3 has become a promising target for anti-tuberculosis drugs. Although many inhibitors targeting MmpL3 have been discovered, their unbinding mechanisms and kinetics remain poorly understood. In this study, the τ-random acceleration molecular dynamics (τRAMD) and steered molecular dynamics (SMD) methods were employed to investigate the unbinding mechanisms and kinetics of four representative MmpL3 inhibitors: SQ109, AU1235, NITD349, and BM212. Analysis of 320 RAMD dissociation trajectories revealed considerable diversity in the dissociation pathways for these inhibitors, dissociating into intracellular, extracellular, or transmembrane regions. Notably, the H4H5H10 pathway, dissociating to the intracellular region, was the primary route. Also, τRAMD results demonstrated a strong correlation between the computed relative residence times and experimental data. Furthermore, SMD simulations along the H4H5H10 pathway indicated that SQ109, AU1235, and NITD349 disrupted hydrogen bonding with MmpL3 prior to dissociation. Meanwhile, inhibitor BM212 underwent conformational adjustments within the binding pocket. All these inhibitors must traverse the channel formed by Phe255 and Phe644 via the H4H5H10 pathway, necessitating the overcoming of significant energy barriers. Based on these findings, we suggest that enhancing inhibitor interactions with MmpL3, such as through hydrogen bonding or increasing inhibitor size to create larger physical barriers (e.g., interactions with Phe255 and Phe644), may prolong the inhibitors' residence times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.